טוען...
Preclinical efficacy of hK2 targeted [(177)Lu]hu11B6 for prostate cancer theranostics
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR) expression. Targeting proteins that are expressed as...
שמור ב:
| הוצא לאור ב: | Theranostics |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ivyspring International Publisher
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6531309/ https://ncbi.nlm.nih.gov/pubmed/31149033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.31179 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|